| Description |
1 online resource |
|
text txt rdacontent |
|
computer c rdamedia |
|
online resource cr rdacarrier |
| Series |
Human sexuality |
|
Sexology research and issues |
|
Human sexuality.
|
|
Sexology research and issues.
|
| Bibliography |
Includes bibliographical references and index. |
| Note |
Print version record. |
| Contents |
ERECTILE DYSFUNCTION -- ERECTILE DYSFUNCTION -- Contents -- Foreword -- Part One -- Introduction -- References -- A Primary Care Approach to Erectile Dysfunction -- Abstract -- Introduction -- Assessment of ED -- Common Causes of Erectile Dysfunction -- Baseline Investigations -- Men in the Following Categories Require Referral -- Developing a Treatment Plan -- Phase 1: Stabilise General Clinical Condition -- Phase 2: Treat Correctable Causes -- Phase 3: Initiate Specific Therapy for Erectile Dysfunction -- Phase 4: Onward Referral |
|
Conclusion References -- Erectile Dysfunction: Causes, Risk Factors and Management -- Abstract -- Introduction -- Epidemiology -- Physiology of Erection -- Pathophysiology of Erectile Dysfunction -- Psychogenic ED -- Neurogenic ED -- Hormonal Causes of ED -- Vascular Causes of ED -- Drug-Induced Erectile Dysfunction -- Erectile Dysfunction due to other Systemic Diseases and Ageing -- Renal Disease -- Spinal Cord Injury -- Correlations of ED with CAD and DM -- Correlation of ED with Lower Urinary Tract Symptoms (LUTS) |
|
Clinical Evaluation Quantification of the Severity of Erectile Dysfunction and Improvement -- Physical Examination -- Laboratory Studies -- Special Studies -- Penile Duplex Doppler Imaging -- Management of Erectile Dysfunction -- I. Medical and other Non-surgical Treatment -- Phosphodiesterase Type 5 Inhibitors (PDE5 Inhibitors) -- 1. Sildenafil Citrate (Viagra) -- 2. Vardenafil (Levitra) -- 3. Tadalafil (Cialis) -- 4. Use of PDE5 Inhibitors and Cardiovascular Safety -- Apomorphine (Uprima) -- Adrenergic-Receptor Antagonists |
|
1. Phentolamine (Regitine) 2. Yohimbine -- Trazodone (Desyrel, Mesyrel) -- Dietary Supplements and Erectile Dysfunction -- 1. Ginkgo Bilboa -- 2. L-Arginine -- Intracavernosal and Intraurethral Therapy -- 1. Alprostadil (Prostaglandin E1, Caverject, Medicated Urethral System for Erection) -- 2. Papaverine -- 3. Phentolamine (Regitine) -- 4. Moxisylyte Chlorohydrate -- 5. Chlorpromazine (Thorazine) -- 6. Vasoactive Intestinal Polypeptide (VIP) -- Testosterone -- Vacuum Constrictive Device -- II. Surgical Treatment |
|
Penile Prostheses Implantation Penile Revascularization -- Venectomy -- III. Future Treatments -- Gene Therapy -- 1. Gene Therapy and NOS -- 2. Gene Therapy and the Human Calcium-Sensitive Potassium Channel Subtype -- 3. Gene Therapy and Vascular Endothelial Growth Factor (VEGF) and other Molecular Targets -- Conclusion -- References -- Current and Emerging Novel Diagnostic Tools for the Diagnosis of Male Erectile Dysfunction -- Abstract -- Introduction -- Consensus and Major International Guidelines on the Investigations of ED |
| Subject |
Impotence.
|
|
Erectile Dysfunction |
|
Impuissance sexuelle.
|
|
HEALTH & FITNESS -- Diseases -- General.
|
|
MEDICAL -- Clinical Medicine.
|
|
MEDICAL -- Diseases.
|
|
MEDICAL -- Evidence-Based Medicine.
|
|
MEDICAL -- Internal Medicine.
|
|
Impotence
|
| Added Author |
Grant, Paul Steven, editor.
|
| Other Form: |
Print version: Erectile dysfunction. New York : Nova Science Publishers, [2012] 9781619423169 (DLC) 2012938162 |
| ISBN |
9781619423206 (eBook) |
|
1619423200 |
|
1619423162 |
|
9781619423169 |
|
9781619423169 (hardcover) |
| Standard No. |
DEBBG BV043774742 |
|
DEBSZ 472770934 |
|
